PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.09
D/E ratio at 50-90% of Medical - Pharmaceuticals median of 0.16. Peter Lynch would verify if this conservative capital structure supports growth opportunities.
-2.09
Net cash position versus Medical - Pharmaceuticals median net debt of 0.46. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
468.29
Positive coverage while Medical - Pharmaceuticals median is negative. Peter Lynch would investigate our competitive advantages in a distressed sector.
0.71
Current ratio below 50% of Medical - Pharmaceuticals median of 2.42. Michael Burry would check for immediate refinancing needs.
0.13%
Intangibles less than half the Medical - Pharmaceuticals median of 4.18%. Warren Buffett would verify if this conservative approach misses valuable brand-building opportunities.